Alector Inc.

Industry · 10 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Continuation Study for Latozinemab Neurodegenerative Diseases	Phase 3	2023-12-08
Terminated	A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease Alzheimer's Disease	Phase 2	2023-01-04
Terminated	A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS Amyotrophic Lateral Sclerosis	Phase 2	2021-09-02
Completed	A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease Alzheimer Disease	Phase 2	2021-01-22
Terminated	A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) Frontotemporal Dementia	Phase 3	2020-07-23
Completed	A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 Healthy	Phase 1	2019-12-14
Completed	A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRON Frontotemporal Dementia	Phase 2	2019-09-27
Completed	First in Human Study for Safety and Tolerability of AL003. Healthy, Alzheimer Disease	Phase 1	2019-03-29
Completed	A Phase I Study for Safety and Tolerability of AL002. Healthy, Alzheimer Disease	Phase 1	2018-11-12
Completed	A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (G Healthy, Frontotemporal Dementia	Phase 1	2018-09-14